MX2012001691A - Composiciones de linaclotida que se desintegran oralmente. - Google Patents
Composiciones de linaclotida que se desintegran oralmente.Info
- Publication number
- MX2012001691A MX2012001691A MX2012001691A MX2012001691A MX2012001691A MX 2012001691 A MX2012001691 A MX 2012001691A MX 2012001691 A MX2012001691 A MX 2012001691A MX 2012001691 A MX2012001691 A MX 2012001691A MX 2012001691 A MX2012001691 A MX 2012001691A
- Authority
- MX
- Mexico
- Prior art keywords
- linaclotide
- orally disintegrating
- disintegrating compositions
- compositions
- processes
- Prior art date
Links
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical group C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 title abstract 2
- 229960000812 linaclotide Drugs 0.000 title abstract 2
- 108010024409 linaclotide Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas que se disuelven o que se desintegran oralmente que comprenden linaclotida o sales de las mismas farmacéuticamente aceptables, así como también a varios métodos y procesos para la preparación y uso de las composiciones.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23331409P | 2009-08-12 | 2009-08-12 | |
| PCT/US2010/045174 WO2011019819A1 (en) | 2009-08-12 | 2010-08-11 | Orally disintegrating compositions of linaclotide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012001691A true MX2012001691A (es) | 2012-02-29 |
Family
ID=42752999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012001691A MX2012001691A (es) | 2009-08-12 | 2010-08-11 | Composiciones de linaclotida que se desintegran oralmente. |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20150031632A1 (es) |
| CA (1) | CA2770334A1 (es) |
| MX (1) | MX2012001691A (es) |
| WO (1) | WO2011019819A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2328601T1 (sl) | 2008-08-15 | 2020-08-31 | Ironwood Pharmaceuticals, Inc. | Linaklotid vsebujoče formulacije za oralno dajanje |
| US8748573B2 (en) | 2009-08-06 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
| ES2638589T3 (es) | 2010-02-17 | 2017-10-23 | Ironwood Pharmaceuticals, Inc. | Tratamientos para trastornos intestinales |
| CA2808091C (en) | 2010-08-11 | 2019-05-21 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
| JP2013540732A (ja) * | 2010-09-11 | 2013-11-07 | アイロンウッド ファーマシューティカルズ， インコーポレイテッド | 便秘型過敏性腸症候群の処置 |
| JP6312592B2 (ja) | 2011-08-17 | 2018-04-18 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | 消化器疾患の治療 |
| UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
| EP3180016A4 (en) | 2014-08-11 | 2018-01-03 | Sun Pharmaceutical Industries Ltd | Linaclotide stable composition |
| WO2017060500A1 (en) | 2015-10-07 | 2017-04-13 | Cyprumed Gmbh | Pharmaceutical formulations for the oral delivery of peptide drugs |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1171134A4 (en) * | 1999-03-16 | 2005-01-05 | Pentech Pharmaceuticals Inc | CONTROLLED DELIVERY OF SILDENAFIL ADMINISTERED BY SUBLINGUAL OR ORAL |
| US20060110478A1 (en) * | 2004-11-22 | 2006-05-25 | Mccleary Edward L | Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction |
| DE10207394B4 (de) | 2002-02-21 | 2007-03-29 | Lts Lohmann Therapie-Systeme Ag | Geschmacksmaskierte oblatenförmige Arzneizubereitung |
| US7304036B2 (en) * | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7799790B2 (en) * | 2006-07-20 | 2010-09-21 | Helm Ag | Amorphous aripiprazole and process for the preparation thereof |
-
2010
- 2010-08-11 CA CA2770334A patent/CA2770334A1/en not_active Abandoned
- 2010-08-11 MX MX2012001691A patent/MX2012001691A/es not_active Application Discontinuation
- 2010-08-11 WO PCT/US2010/045174 patent/WO2011019819A1/en active Application Filing
-
2014
- 2014-10-09 US US14/510,802 patent/US20150031632A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2770334A1 (en) | 2011-02-17 |
| WO2011019819A1 (en) | 2011-02-17 |
| US20150031632A1 (en) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| MX2012001691A (es) | Composiciones de linaclotida que se desintegran oralmente. | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
| WO2010092090A3 (en) | Novel salts of sitagliptin | |
| GEP20227397B (en) | Inhibitors of influenza viruses replication | |
| MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| IN2012DN01233A (es) | ||
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| TN2012000126A1 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
| IN2012DN02177A (es) | ||
| IN2012DN00754A (es) | ||
| IN2012DN03182A (es) | ||
| MX2011013032A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| IN2013MU03583A (es) | ||
| WO2011009938A3 (en) | Stambomycin and derivatives, their production and their use as drugs | |
| MX2011011109A (es) | Formulaciones orales de bendamustina. | |
| WO2010049449A3 (en) | Novel salts of sunitinib | |
| PH12013500784A1 (en) | Pharmaceutical compositions comprising nano size droplets of skin whitening agents | |
| WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
| TN2012000105A1 (en) | Spirolactam derivatives and uses of same | |
| EA201200485A1 (ru) | Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол | |
| MX2011008645A (es) | Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa. | |
| UA103996C2 (en) | Ivabradine hydrobromide | |
| WO2010119450A3 (en) | An improved process for the preparation of desmopressin or its pharmaceutically acceptable salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |